Pharma Tips

Cipla posts 15 percent rise in Q3 profit

By: Pharma News | Views: 1864 | Date: 26-Feb-2015

Cipla, the pharmaceutical firm, on Thursday reported 15.31 per cent increase in its consolidated net profit at Rs 327.85 crore in the third quarter ended December 31, 2014.The company, which had posted a net profit of Rs 284.31 crore in the same period last fiscal, said it would acquire 60 per cent stake in Jay Precision Pharmaceuticals for a cash consideration of Rs 96 crore.


Cipla posts 15 percent rise in Q3 profit, to buy 60 per cent in Jay Precision

Cipla,  the pharmaceutical firm, on Thursday reported 15.31 per cent increase in its consolidated net profit at Rs 327.85 crore in the third quarter ended December 31, 2014.


The company, which had posted a net profit of Rs 284.31 crore in the same period last fiscal, said it would acquire 60 per cent stake in Jay Precision Pharmaceuticals for a cash consideration of Rs 96 crore.

Net sales during the period under review stood at Rs 2,624.71 crore as against 2,567.97 crore in the year-ago period, the company said in a filing to the Bombay Stock Exchange(BSE).

Domestic sales grew by 14.2 per cent to Rs 1,199 crore during the period under review, up from Rs 1,050 crore in the year-ago period, it added.

The growth in domestic sales was largely on account of growth in respiratory, anti-infectives, cardiac and gastro intestinal therapies, the company said.

Exports, however, saw a decline during the quarter as overseas shipments of formulations decreased by 6.2 per cent to Rs 1,275 crore, down from Rs 1,360 crore in the same period last fiscal.

Active pharmaceutical ingredients exports also declined to Rs 151 crore in the third quarter, from Rs 158 crore in same period last fiscal, it said.

Shares of Cipla ended the day at Rs 662 per scrip, up 4.07 per cent from the previous close on the BSE.

In a separate fling, Cipla said it has signed a definitive agreement to acquire 60 per cent stake in Jay Precision Pharmaceuticals from the existing shareholders.

Jay Precision is an existing supplier of respiratory devices to the company and has a manufacturing facility at Vasai, Maharashtra.

Considering company's leading position in inhalation therapy, this transaction is aimed at integrating the value chain and will serve as platform for development of next generation respiratory devices, Cipla said.

Pharmaceutical undertaking of Jay Precision Products (India) was demerged into Jay Precision effective January 1, 2014.

Turnover of Jay Precision for the year ended March 31, 2014 was Rs 30 crore, the filing said.

The transaction is expected to be completed by end of this financial year, subject to completion of certain conditions precedent, Cipla said.

Previous Page Next Page

People Searching On This Page:

Related Pages


Biocon net profit falls 13% to Rs 91 cr; to offload 10-15% in Syngene

Biocon net profit falls 13% to Rs 91 cr; to offload 10-15% in Syngene

News | Pharma Companies
Date:
11-Feb-2015  Views: 779

Biotech firm Biocon on Thursday reported a 13 per cent fall in net profit for October-December quarter at Rs 91 crore and said it will sell 10-15 per ...
Wockhardt net profit rises 14.05% in Q3

Wockhardt net profit rises 14.05% in Q3

News | Pharma Companies
Date:
10-Feb-2015  Views: 794

Pharmaceuticals firm Wockhardt on Wednesday reported a 14.05 per cent rise in consolidated net profit at Rs 347.25 crore for the third quarter ended D ...
Dr Reddy's net profit falls 7.09% in Q3

Dr Reddy's net profit falls 7.09% in Q3

News | Pharma Companies
Date:
05-Feb-2015  Views: 708

Drug major Dr Reddy's Laboratories on Thursday reported a 7.09 per cent decline in its consolidated net profit at Rs 574.53 crore for the quarter ende ...
Lupin reports 26% rise in Q3 net profit

Lupin reports 26% rise in Q3 net profit

News | Pharma Companies
Date:
03-Feb-2015  Views: 695

Drug firm Lupin on Tuesday reported a 26.32 per cent rise in its consolidated net profit at Rs 601.45 crore for the quarter ended December 2014 on acc ...
Sun Pharma Q4 net profit up 57 percent, beats expectations

Sun Pharma Q4 net profit up 57 percent, beats expectations

News | Pharma Companies
Date:
22-Jul-2014  Views: 1335

Sun Pharmaceutical Industries, India's third-largest drugmaker by revenue, has reported a 57 per cent jump in fourth-quarter net profit, slightly abov ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

81  + 4 =     
Comments

Google : 93 times | Yahoo : 13 times | Bing : 4 times |